Safety and Efficacy Study of Umbilical Cord Blood-Drived Mesenchymal Stem Cells to Promote Engraftment of Unrelated Hematopoietic Stem Cell Transplantation

NCT ID: NCT00823316

Last Updated: 2012-04-23

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-08-31
• Study Completion Date: 2010-02-28

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of PROMOSTEM (human umbilical cord blood-derived mesenchymal stem cells) at a dose of 1 and 5x1,000,000 hMSC/kg in subject for the promotion of an engraftment and prevention of graft rejection and Graft-Versus-Host Disease after unrelated hematopoietic stem cell transplantation for children with acute leukemia.

Detailed Description

• Hematopoietic stem cell transplantation (HSCT) is a procedure in which progenitor cells capable of reconstituting normal bone marrow function are administered to a patient. This procedure has been used to treat adults and children with life-threatening hematological malignancies and congenital immunodeficiency disorders.
• In HSCT, therapeutic goal is an elimination of disease and enrichment of regenerating capacity to achieve engraftments resulting in continued generation of functional blood elements from the engrafted living cells. Transplantation of unrelated hematopoietic stem cells originating either from adult bone marrow or from peripheral blood often leads to graft-versus host-disease (GvHD), opportunistic infections and graft failure after transplantation.
• In HSCT, MSC have been used as a therapy for GvHD and other complications. The aim of MSC infusions in HSCT is to use the cells' immunomodulatory effects to promote engraftment and to reduce the immunological reactions giving rise to GvHD.
• There is a growing interest in co-transplantation of MSC and HSC to improve the donor outcome in the unrelated HSCT condition.

Conditions

Acute Leukemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

1

at a dose of 1x1,000,000 hMSC/kg

Group Type: EXPERIMENTAL

Human umbilical cord blood-derived mesenchymal stem cells

Intervention Type: BIOLOGICAL

1x1,000,000 hMSC/kg, IV after unrelated HSCT

2

at a dose of 5x1,000,000 hMSC/kg

Group Type: EXPERIMENTAL

Human umbilical cord blood-derived mesenchymal stem cells

Intervention Type: BIOLOGICAL

5x1,000,000 hMSC/kg, IV after unrelated HSCT

Interventions

Human umbilical cord blood-derived mesenchymal stem cells

1x1,000,000 hMSC/kg, IV after unrelated HSCT

Intervention Type: BIOLOGICAL

Human umbilical cord blood-derived mesenchymal stem cells

5x1,000,000 hMSC/kg, IV after unrelated HSCT

Intervention Type: BIOLOGICAL

Other Intervention Names

PROMOSTEM; PROMOSTEM

Eligibility Criteria

Inclusion Criteria

1. Patient age 2~19 years old with plan to have unrelated hematopoietic stem cell transplantation with acute leukemia

2. Patient never has an experience of hematopoietic stem cell transplantation

3. Patient must have an acute leukemia with a complete remission.

4. Patients must have an ECOG 0~2.

5. No moderate or sever organ dysfunction : Ejection fraction > 45%; Creatinine <2.0 mg/ml; Serum bilirubin < 2 mg/ml; AST/ALT < 200 IU/L.

6. Patient must not have an transplantation with different source of hematopoietic stem cell such as bone marrow and cord blood.

7. Patient must not have an infection needed an administration of non-oral antibiotics.

8. No active severe infection derived form virus or fungus.

9. Each patient / patient's guardian must sign written informed consent.

Exclusion Criteria

1. Patient has previously received hematopoietic stem cell transplantation.

2. Patient plans to have a related hematopoietic stem cell transplantation.

3. Patient has a severe internal disease.

4. Patient has enrolled another clinical trial study within last 4 weeks.

• Minimum Eligible Age: 2 Years
• Maximum Eligible Age: 19 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medipost Co Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hong Hoe Koo, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Samsung Medical Center

Locations

Samsung Medical Center

Seoul, , South Korea

Countries

South Korea

Other Identifiers

MP-CR-MSC003

Identifier Type: -

Identifier Source: org_study_id